Parabilis Medicines Inc (PBLS)

$30.31 -1.29 (-4.08%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -145.89M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,600,400
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A
kgervis
kgervis Jun. 22 at 3:34 PM
$PBLS let’s pump
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 22 at 2:58 PM
$PBLS added xbi could be new leader who knows
0 · Reply
BanditQ
BanditQ Jun. 20 at 7:45 PM
$PBLS way too overvalued for a pre-clin biotech
0 · Reply
History101
History101 Jun. 19 at 8:48 PM
$PBLS 192 watching 6/19/2026
0 · Reply
PlannedTrading101
PlannedTrading101 Jun. 17 at 4:28 PM
$PBLS
0 · Reply
invvestigator
invvestigator Jun. 17 at 3:47 PM
$PBLS idiot Indian beggars pumping this one on social media by misrepresenting a Form 4 filing for stock conversion of pre IPO shares. Shame on you brokies for trying to pump and scam retail on this high risk biotech. 😒
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 17 at 2:29 PM
PREMARKET MOVERS - JUNE 17 SPACE / NEXT-GEN INFRASTRUCTURE • $ASTS +5% — rising after successful BlueBird 8–10 satellite deployment via SpaceX Falcon 9, reinforcing space-based connectivity rollout narrative ENERGY / STORAGE • $EOSE +6% — momentum building after commercial production start at Battery Line 2 (Thorn Hill) plus visibility into multi-GWh storage pipeline and agreements FINTECH / RETAIL FLOW • $HOOD +2% — modest strength alongside retail trading and crypto-linked sentiment support BIOTECH • $PBLS +10% — standout early biotech mover with strong premarket volume expansion • $PTCT +5% — continuing relative strength within higher-beta biotech group Theme today: capital rotation into high-beta infrastructure + event-driven names across space, storage, and biotech while broader risk appetite remains constructive.
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 17 at 2:27 PM
$PBLS small pos add
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 17 at 2:15 PM
$PBLS watching here
0 · Reply
TheZorroWay
TheZorroWay Jun. 17 at 11:43 AM
$PBLS everyone talking about the $SPCX IPO is sleeping on the largest ever biotech IPO where insiders are buying into the IPO instead of waiting to sell… $VKTX $MRNA https://x.com/wayofzorro/status/2067211083215962516?s=46
0 · Reply
Latest News on PBLS
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 11, 2026, 4:05 PM EDT - 13 days ago

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Parabilis Medicines off highs, but still up over 50% from IPO price

2026-06-10T18:20:10.000Z - 14 days ago

Parabilis Medicines off highs, but still up over 50% from IPO price

Parabilis Medicines opens at $33.35, IPO priced at $20.00

2026-06-10T17:40:08.000Z - 14 days ago

Parabilis Medicines opens at $33.35, IPO priced at $20.00

Parabilis Medicines 33.5M share IPO priced at $20.00

2026-06-10T01:35:18.000Z - 15 days ago

Parabilis Medicines 33.5M share IPO priced at $20.00

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Jun 9, 2026, 8:22 PM EDT - 15 days ago

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines aims to raise $633 million in upsized US IPO

Jun 9, 2026, 6:16 AM EDT - 15 days ago

Parabilis Medicines aims to raise $633 million in upsized US IPO

Parabilis Medicines aims to raise up to $475 million in US IPO

Jun 4, 2026, 6:46 AM EDT - 20 days ago

Parabilis Medicines aims to raise up to $475 million in US IPO

Biopharmaceutical firm Parabilis Medicines files for US IPO

May 19, 2026, 5:14 PM EDT - 5 weeks ago

Biopharmaceutical firm Parabilis Medicines files for US IPO

Parabilis Medicines IPO Registration Document (S-1)

May 19, 2026, 4:53 PM EDT - 5 weeks ago

Parabilis Medicines IPO Registration Document (S-1)

kgervis
kgervis Jun. 22 at 3:34 PM
$PBLS let’s pump
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 22 at 2:58 PM
$PBLS added xbi could be new leader who knows
0 · Reply
BanditQ
BanditQ Jun. 20 at 7:45 PM
$PBLS way too overvalued for a pre-clin biotech
0 · Reply
History101
History101 Jun. 19 at 8:48 PM
$PBLS 192 watching 6/19/2026
0 · Reply
PlannedTrading101
PlannedTrading101 Jun. 17 at 4:28 PM
$PBLS
0 · Reply
invvestigator
invvestigator Jun. 17 at 3:47 PM
$PBLS idiot Indian beggars pumping this one on social media by misrepresenting a Form 4 filing for stock conversion of pre IPO shares. Shame on you brokies for trying to pump and scam retail on this high risk biotech. 😒
0 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 17 at 2:29 PM
PREMARKET MOVERS - JUNE 17 SPACE / NEXT-GEN INFRASTRUCTURE • $ASTS +5% — rising after successful BlueBird 8–10 satellite deployment via SpaceX Falcon 9, reinforcing space-based connectivity rollout narrative ENERGY / STORAGE • $EOSE +6% — momentum building after commercial production start at Battery Line 2 (Thorn Hill) plus visibility into multi-GWh storage pipeline and agreements FINTECH / RETAIL FLOW • $HOOD +2% — modest strength alongside retail trading and crypto-linked sentiment support BIOTECH • $PBLS +10% — standout early biotech mover with strong premarket volume expansion • $PTCT +5% — continuing relative strength within higher-beta biotech group Theme today: capital rotation into high-beta infrastructure + event-driven names across space, storage, and biotech while broader risk appetite remains constructive.
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 17 at 2:27 PM
$PBLS small pos add
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Jun. 17 at 2:15 PM
$PBLS watching here
0 · Reply
TheZorroWay
TheZorroWay Jun. 17 at 11:43 AM
$PBLS everyone talking about the $SPCX IPO is sleeping on the largest ever biotech IPO where insiders are buying into the IPO instead of waiting to sell… $VKTX $MRNA https://x.com/wayofzorro/status/2067211083215962516?s=46
0 · Reply
jimbecker
jimbecker Jun. 17 at 11:29 AM
$PBLS 100 Shares @ $30.21. FOMO is a dangerous thing.
0 · Reply
jimbecker
jimbecker Jun. 17 at 11:20 AM
$PBLS Gap up premarket. Whale took a massive position last week. Looking for a good entry.
0 · Reply
Irish_lass
Irish_lass Jun. 15 at 9:17 PM
$PBLS Waiting for this to settle before the next entry.
0 · Reply
JFais
JFais Jun. 15 at 4:09 PM
$PBLS interesting IPO on current weakness (DD list for when I get to it)
0 · Reply
justiceforb_85
justiceforb_85 Jun. 12 at 11:15 PM
$PBLS strong data for zolucatetide in ameloblastoma, craniopharyngioma, and desmoid tumors. Added more on today's dip.
0 · Reply
Irish_lass
Irish_lass Jun. 11 at 8:29 PM
$PBLS https://investors.parabilismed.com/news-releases/news-release-details/parabilis-medicines-announces-closing-upsized-initial-public
0 · Reply
novumcarpediem
novumcarpediem Jun. 11 at 4:02 PM
$PBLS https://cafepharma.com/boards/threads/what-happened-to-mathai-mammen.680330/page-2
0 · Reply
novumcarpediem
novumcarpediem Jun. 11 at 3:27 PM
$PBLS
0 · Reply
novumcarpediem
novumcarpediem Jun. 11 at 3:21 PM
$PBLS CEO is a known sexual harasser in his J&J days! https://eu.mycentraljersey.com/story/news/local/courts/2020/12/17/ex-johnson-johnson-exec-alleges-discrimination-retaliation-suit/3941187001/
0 · Reply
topstockalerts
topstockalerts Jun. 11 at 2:47 AM
Top Gainers PT2 $IZM $HXHX $HKIT $PBLS $BATL
0 · Reply
topstockalerts
topstockalerts Jun. 10 at 9:48 PM
Top Gainers PT2 $IZM $HXHX $HKIT $PBLS $BATL
0 · Reply
Irish_lass
Irish_lass Jun. 10 at 9:04 PM
$PBLS “To our knowledge, our lead product candidate, zolucatetide, is the first-ever drug to directly target the interaction between b-catenin and the T-cell factor (“TCF”) family of transcription factors. This is the central node in the Wnt/b-catenin cell signaling pathway, which regulates cell proliferation and differentiation and whose hyperactivation is a driver of millions of cancer cases annually across many tumor types. Drugging this critical node eluded three decades of intensive efforts to do so across the pharmaceutical industry. Zolucatetide has been evaluated in over 150 patients to date and has generated promising clinical data in a range of solid tumors driven by alterations in the Wnt/b-catenin pathway. In our lead indication, desmoid tumors, we have observed tumor reductions in 100% of patients with a 74% objective response rate (“ORR”). We plan to initiate a global registrational Phase 3 trial for zolucatetide in patients with desmoid tumors in the 1H 2027”
0 · Reply